Effect of best practice advisory on the administration of contraindicated medications to hospitalized patients with Parkinson's disease and related disorders.

"Conflict of interest KA was supported by the Michael J Fox Edmund J. Safra Fellowship in Movement Disorders from July 2,107–July 2019. She previously served as Investigator and/or medical monitor for clinical trials supported by Aptinyx Inc. Genentech Roche Ltd., EIP Pharma Inc., Michael J Fox foundation for PD research, NINDS, and Acadia Pharmaceuticals Inc., and Biogene. She previously served as Co-I of a Lewy Body Dementia Association Research Center of Excellence site. IR serves as Director of the University of Rochester Parkinson’s Foundation Center of Excellence and her contributions to this article were supported by a Parkinson’s Foundation Community Grant, Parkinson’s Disease Hospital Optimization Project (PD-HOP) for which she served as PI. Dr. Richard has received research and/or training grants from NIH, Parkinson’s Foundation and the Michael J. Fox Foundation. Dr. Richard has served as a site investigator and/or co-investigator for clinical research studies sponsored by grants from Industry to the University of Rochester, currently including F. Hoffmann-La Roche Ltd., Acadia Pharm, and Jazz Pharmaceuticals. The sponsors were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The work presented here was part of the Parkinson’s Disease Hospital Optimization Project (PD-HOP), which was supported by a Parkinson’s Foundation Community Grant (awarded to IR; grant no. PF-CGP_19166)."